Kirk Robarge - Concepedia

Author

Kirk Robarge

Also Known As

K Robarge, K. D. ROBARGE, K. D. Robarge, K. Robarge, K.D. Robarge, Kirk D Robarge, Kirk D. Robarge, Kirk Robarge, Robarge, Kirk

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

WuXi AppTec (China)University of California, Irvine Irvine University Array BioPharma (United States)University of California, Berkeley

About

Kirk Robarge is an author at WuXi AppTec (China) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.8K
2	Biochemistry	17	18	983
3	Natural Sciences	15	17	1K
4	Engineering	7	7	275
5	Health Sciences	1	1	20

Kirk Robarge

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
GDC-0449—A potent inhibitor of the hedgehog pathway Kirk Robarge, Shirley A. Brunton, Georgette M. Castanedo, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologySignaling PathwayMolecular PathwayMedicinePharmacology	2009	385
Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance Gerrit J.P. Dijkgraaf, Bruno Alicke, Lasse Weinmann, Cancer Research Molecular BiologyGliomaSmall Molecule InhibitionTumor BiologyDrug Resistance	2010	363
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition Aaron Boudreau, Hans E. Purkey, A. Hitz, Nature Chemical Biology Systems BiologyBiochemistryLdha InhibitionLipid PeroxidationMetabolic Regulation	2016	251
Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development James F. Blake, Michael Burkard, Jocelyn Chan, Journal of Medicinal Chemistry Erk Kinase ActivityCellular PharmacologyTumor BiologyPre-clinical PharmacologyMolecular Pharmacology	2016	156
From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold Robert S. McDowell, Brent Blackburn, Thomas R. Gadek, Journal of the American Chemical Society Altmetric Attention ScorePeptide SciencePharmacotherapyPeptide TherapeuticsChemical Biology	1994	99
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists Benjamin P. Fauber, Alberto Gobbi, Kirk Robarge, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryBiochemistryNatural SciencesMedicine	2015	70
Accelerated inverse electron demand Diels-Alder reactions of 1-oxa-1,3-butadienes: [4 + 2] cycloaddition reactions of .beta.,.gamma.-unsaturated .alpha.-keto esters Dale L. Boger, Kirk Robarge The Journal of Organic Chemistry Chemical EngineeringMolecular SciencesEngineeringAlkene MetathesisBiochemistry	1988	68
From Peptide to Non-Peptide. 3. Atropisomeric GPIIbIIIa Antagonists Containing the 3,4-Dihydro-1<i>H</i>-1,4-benzodiazepine-2,5-dione Nucleus Brent Blackburn, Arthur Lee, Mark Baier, Journal of Medicinal Chemistry Peptide SciencePharmacotherapyPeptide TherapeuticsChemical BiologyPharmaceutical Chemistry	1997	58
Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-<i>N</i>-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor Harvey Wong, J.Z. Chen, Bilin Chou, Xenobiotica Pharmaceutical ScienceOral BioavailabilityChemoprevention StrategySelective HedgehogPathology	2009	56
Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice Hans E. Purkey, Kirk Robarge, Jinhua Chen, ACS Medicinal Chemistry Letters	2016	56

Page 1